Cargando…

The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE

AIM: Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to pepti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wetz, Christoph, Genseke, Philipp, Apostolova, Ivayla, Furth, Christian, Ghazzawi, Sammy, Rogasch, Julian M. M., Schatka, Imke, Kreissl, Michael C., Hofheinz, Frank, Grosser, Oliver S., Amthauer, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519899/
https://www.ncbi.nlm.nih.gov/pubmed/31091247
http://dx.doi.org/10.1371/journal.pone.0216781
_version_ 1783418687767707648
author Wetz, Christoph
Genseke, Philipp
Apostolova, Ivayla
Furth, Christian
Ghazzawi, Sammy
Rogasch, Julian M. M.
Schatka, Imke
Kreissl, Michael C.
Hofheinz, Frank
Grosser, Oliver S.
Amthauer, Holger
author_facet Wetz, Christoph
Genseke, Philipp
Apostolova, Ivayla
Furth, Christian
Ghazzawi, Sammy
Rogasch, Julian M. M.
Schatka, Imke
Kreissl, Michael C.
Hofheinz, Frank
Grosser, Oliver S.
Amthauer, Holger
author_sort Wetz, Christoph
collection PubMed
description AIM: Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to peptide receptor radionuclide therapy (PRRT). Secondly, we correlated ASP derived form a pre-therapeutic OctreoScan (ASP([In])) and an intra-therapeutic [(177)Lu]-SPECT/CT (ASP([Lu])). MATERIALS AND METHODS: Data from first therapy cycle [(177)Lu-DOTA(0)-Tyr(3)]octreotate ([(177)Lu]-DOTATATE)-PRRT was retrospectively analyzed in 33 patients (m = 20; w = 13; median age, 72 [46–88] years). The evaluation of response to PRRT was performed according to RECIST 1.1 in responding lesions [RL (SD, PR, CR), n = 104] and non-responding lesions [NRL (PD), n = 27]. The association of SSR tumor heterogeneity with morphological response was evaluated by Kruskal-Wallis test and receiver operating characteristic curve (ROC). The optimal threshold for separation (RL vs. NRL) was calculated using the Youden-index. Relationship between pre- and intra-therapeutic ASP was determined with Spearman’s rank correlation coefficient (ρ) and Bland-Altman plots. RESULTS: A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5) were analyzed. Lesions with higher ASP values showed a significantly poorer response to PRRT (PD, median: 11.3, IQR: 8.5–15.5; SD, median: 3.4, IQR: 2.1–4.5; PR, median 1.7, IQR: 0.9–2.8; CR, median: 0.5, IQR: 0.0–1.3); Kruskal-Wallis, p<0.001). ROC analyses revealed a significant separation between RL and NRL for ASP after 4 months (AUC 0.85, p<0.001) and after 12 months (AUC 0.94, p<0.001). The optimal threshold for ASP was >5.45% (sensitivity 96% and specificity 82%). The correlation coefficient of pre- and intra-therapeutic ASP revealed ρ = 0.72 (p <0.01). The mean absolute difference between ASP([In]) and ASP([Lu]) was -0.04 (95% Limits of Agreement, -6.1–6.0). CONCLUSION: Pre- and intra-therapeutic ASP shows a strong correlation and might be an useful tool for therapy monitoring.
format Online
Article
Text
id pubmed-6519899
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65198992019-05-31 The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE Wetz, Christoph Genseke, Philipp Apostolova, Ivayla Furth, Christian Ghazzawi, Sammy Rogasch, Julian M. M. Schatka, Imke Kreissl, Michael C. Hofheinz, Frank Grosser, Oliver S. Amthauer, Holger PLoS One Research Article AIM: Purpose of this study was to evaluate the association of the spatial heterogeneity (asphericity, ASP) in intra-therapeutic SPECT/ CT imaging of somatostatin receptor (SSR) positive metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) for morphological treatment response to peptide receptor radionuclide therapy (PRRT). Secondly, we correlated ASP derived form a pre-therapeutic OctreoScan (ASP([In])) and an intra-therapeutic [(177)Lu]-SPECT/CT (ASP([Lu])). MATERIALS AND METHODS: Data from first therapy cycle [(177)Lu-DOTA(0)-Tyr(3)]octreotate ([(177)Lu]-DOTATATE)-PRRT was retrospectively analyzed in 33 patients (m = 20; w = 13; median age, 72 [46–88] years). The evaluation of response to PRRT was performed according to RECIST 1.1 in responding lesions [RL (SD, PR, CR), n = 104] and non-responding lesions [NRL (PD), n = 27]. The association of SSR tumor heterogeneity with morphological response was evaluated by Kruskal-Wallis test and receiver operating characteristic curve (ROC). The optimal threshold for separation (RL vs. NRL) was calculated using the Youden-index. Relationship between pre- and intra-therapeutic ASP was determined with Spearman’s rank correlation coefficient (ρ) and Bland-Altman plots. RESULTS: A total of 131 lesions (liver: n = 59, lymph nodes: n = 48, bone: n = 19, pancreas: n = 5) were analyzed. Lesions with higher ASP values showed a significantly poorer response to PRRT (PD, median: 11.3, IQR: 8.5–15.5; SD, median: 3.4, IQR: 2.1–4.5; PR, median 1.7, IQR: 0.9–2.8; CR, median: 0.5, IQR: 0.0–1.3); Kruskal-Wallis, p<0.001). ROC analyses revealed a significant separation between RL and NRL for ASP after 4 months (AUC 0.85, p<0.001) and after 12 months (AUC 0.94, p<0.001). The optimal threshold for ASP was >5.45% (sensitivity 96% and specificity 82%). The correlation coefficient of pre- and intra-therapeutic ASP revealed ρ = 0.72 (p <0.01). The mean absolute difference between ASP([In]) and ASP([Lu]) was -0.04 (95% Limits of Agreement, -6.1–6.0). CONCLUSION: Pre- and intra-therapeutic ASP shows a strong correlation and might be an useful tool for therapy monitoring. Public Library of Science 2019-05-15 /pmc/articles/PMC6519899/ /pubmed/31091247 http://dx.doi.org/10.1371/journal.pone.0216781 Text en © 2019 Wetz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Wetz, Christoph
Genseke, Philipp
Apostolova, Ivayla
Furth, Christian
Ghazzawi, Sammy
Rogasch, Julian M. M.
Schatka, Imke
Kreissl, Michael C.
Hofheinz, Frank
Grosser, Oliver S.
Amthauer, Holger
The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
title The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
title_full The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
title_fullStr The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
title_full_unstemmed The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
title_short The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [(177)Lu]-DOTATATE
title_sort association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing prrt with [(177)lu]-dotatate
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519899/
https://www.ncbi.nlm.nih.gov/pubmed/31091247
http://dx.doi.org/10.1371/journal.pone.0216781
work_keys_str_mv AT wetzchristoph theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT gensekephilipp theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT apostolovaivayla theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT furthchristian theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT ghazzawisammy theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT rogaschjulianmm theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT schatkaimke theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT kreisslmichaelc theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT hofheinzfrank theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT grosserolivers theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT amthauerholger theassociationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT wetzchristoph associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT gensekephilipp associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT apostolovaivayla associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT furthchristian associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT ghazzawisammy associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT rogaschjulianmm associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT schatkaimke associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT kreisslmichaelc associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT hofheinzfrank associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT grosserolivers associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate
AT amthauerholger associationofintratherapeuticheterogeneityofsomatostatinreceptorexpressionwithmorphologicaltreatmentresponseinpatientsundergoingprrtwith177ludotatate